Subscribe to Pharmaceutical Processing News

The Lead

Glancy Prongay & Murray LLP Announces Investigation of Amicus Therapeutics

October 12, 2015 | by Business Wire | Comments

Glancy Prongay & Murray LLP announces that it is investigating potential claims on behalf of investors of Amicus Therapeutics, Inc.


Aridis Pharmaceuticals Receives Multiple NIH Grants for Phase 2 Clinical Programs

October 13, 2015 2:51 pm | by PR Newswire | Comments

Aridis Pharmaceuticals, Inc., announced that it has secured several grants which bring Aridis' total non-dilutive funding in excess of $40 million. 


IGI Laboratories to Acquire the Assets of a Canadian Pharmaceutical Company

October 13, 2015 2:39 pm | by PR Newswire | Comments

IGI Laboratories, Inc., announced it has entered into an agreement to acquire the assets of a Canadian pharmaceutical company for $47 million CAD in cash. 


Peak Pharmaceuticals Shifts Focus to Human Product Development

October 13, 2015 2:32 pm | by Marketwired | Comments

Peak Pharmaceuticals, Inc.announced the termination of its licensing agreement with Canna-Pet, LLC.


Manufacturing Tech Orders Down More than 20 Percent in August

October 13, 2015 2:15 pm | by Andy Szal, Digital Reporter | Comments

Orders for manufacturing technology equipment in the U.S. in August were down, according to the latest U.S. Manufacturing Technology Orders report.


Fishing for Proteins: Seaweed, Sugar Beet, and Software are Helping Pharma Companies Make New Drugs

October 13, 2015 2:02 pm | by Tomas Kellner | Comments

Sugar beet and seaweed aren’t the first things that spring to mind when you start thinking about the latest and most promising drugs. But without them, a new class of revolutionary medicines called biologics targeting everything from diabetes and cancer to arthritis and immune disorders would be extremely hard to make.


Amazon Announces New IoT Platform

October 13, 2015 11:03 am | by Andy Szal, Digital Reporter | Comments last week announced plans to join the wave of tech companies investing in the Internet of Things.


Diplomat to Dispense Taiho Drug for the Treatment of mCRC

October 12, 2015 11:35 am | by PR Newswire | Comments

Taiho Oncology Inc.'s combination tablet, recently approved by the FDA, will be dispensed by Diplomat Pharmacy.  


Adaptimmune Therapeutics Announces Expansion Plans in Philidelphia

October 12, 2015 10:21 am | by Globe Newswire | Comments

Adaptimmune Therapeutics plc. announced plans to locate its U.S. headquarters and clinical operations in a newly developed facility to be constructed in Philadelphia. 


Sunshine Biopharma Acquires U.S. Patent

October 9, 2015 3:50 pm | by Marketwired | Comments

Sunshine Biopharma Inc. announces that it has acquired a U.S. patent.


Medline Industries, Inc. Issues a Voluntary Nationwide Recall

October 9, 2015 3:38 pm | by Business Wire | Comments

Medline Industries, Inc. announced that it will initiate a voluntary nationwide recall of lot of tablets.


Ohio Challenges FDA's Stand on Execution Drug

October 9, 2015 3:31 pm | by The Associated Press | Comments

Ohio sent a forceful letter to Washington on Friday asserting that the state believes it can obtain a lethal-injection drug from overseas without violating any laws.


Bristol-Myers Squibb’s Drug Receives Expanded FDA Approval

October 9, 2015 3:17 pm | by Business Wire | Comments

Bristol-Myers Squibb Company announced that the FDA has approved their drug, for intravenous use, for the treatment of patients with metastatic NSCLC with progression on or after platinum-based chemotherapy.


FDA Accepted Vertex Pharmaceutical's sNDA for Priority Review

October 7, 2015 5:35 pm | by Business Wire | Comments

Vertex Pharmaceuticals Incorporated announced that the FDA has accepted for review a sNDA for a drug that treats CF in people ages 2 and older who have one of 23 residual function mutations. 


Nektar Submits Investigational New Drug Application for Solid Tumor Malignancies Treatment

October 7, 2015 5:23 pm | by PR Newswire | Comments

Nektar Therapeutics announced that it has submitted an IND application to the FDA for its lead immuno-oncology candidate.


Marathon Pharmaceuticals Receives Rare Pediatric Disease Designation from FDA

October 7, 2015 5:15 pm | by Business Wire | Comments

Marathon Pharmaceuticals announced that the FDA has granted rare pediatric disease designation for a potential treatment for patients with DMD.



You may login with either your assigned username or your e-mail address.
The password field is case sensitive.